Name | Title | Contact Details |
---|
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Corbus Pharmaceuticals Holdings, Inc.is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
Phycotransgenics, LLC is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
K-LaB Technologies, Inc. is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.